UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Graft dysfunction after orthotopic cardiac transplantation

Author
Michael X Pham, MD, MPH
Section Editor
Sharon A Hunt, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC

INTRODUCTION

The development of ventricular dysfunction after cardiac transplantation, which can be systolic, diastolic, or mixed, should be of major concern. The causes of graft dysfunction in the transplanted heart can be different, more ominous, and in some cases more responsive to treatment than those seen in the native heart. As a result, familiarity with the potential etiologies, coupled with an aggressive and systematic approach, is essential to identify the etiology and begin prompt treatment.

Graft dysfunction can occur as early as the intraoperative period or can develop many years after transplantation. The timing of graft dysfunction (days, weeks to months, or years post-transplantation) is one of the most important clues to establish a diagnosis. Graft dysfunction may present as either heart failure with preserved or reduced ejection fraction, asymptomatic ventricular dysfunction, or by elevated intracardiac filling pressures or depressed cardiac output on right heart catheterization. It can affect the right, left, or both ventricles.

The most common causes of graft dysfunction after transplantation include primary graft dysfunction, which typically manifests within 24 hours after surgery; cardiac allograft rejection, which is more common during the first 6 to 12 months post-transplantation; and cardiac allograft vasculopathy, which can occur at any time. Diagnostic procedures such as endomyocardial biopsy, echocardiography, and coronary angiography are important tools in elucidating the etiology, but all these studies have their limitations. (See "Acute cardiac allograft rejection: Diagnosis" and "Endomyocardial biopsy".)

EARLY GRAFT DYSFUNCTION

Early allograft dysfunction can be apparent in the intraoperative period or can develop within 24 hours after transplant surgery. It can manifest as left ventricular (LV) dysfunction, isolated right ventricular (RV) dysfunction, or biventricular dysfunction, and it is associated with significantly increased 30-day and one-year mortality. Early graft dysfunction is classified as primary or secondary graft dysfunction according to the suspected etiology.

Primary graft dysfunction — Primary Graft Dysfunction (PGD) is currently defined as LV, RV, or biventricular dysfunction that occurs within 24 hours after surgery and is not associated with a discernible cause such as hyperacute rejection, pulmonary hypertension, or uncontrolled intraoperative bleeding resulting in massive blood product transfusions and prolonged graft ischemic time [1]. Prior to the development of a standardized definition for PGD, a survey of 47 international heart transplant centers reported an incidence of PGD of 7.4 percent among 9901 patients who underwent heart transplantation between January and March 2013. The majority of centers required an LV ejection fraction of ≤40 percent and/or the use of mechanical support as criteria for PGD. Mortality among patients reported in this survey was 30 percent at 30 days and 35 percent at one year, and the most common causes of 30-day mortality were multiorgan failure in 70 percent of patients, graft failure in 20 percent, and sepsis in 10 percent [1].

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Jul 07 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant 2014; 33:327.
  2. Jahania MS, Sanchez JA, Narayan P, et al. Heart preservation for transplantation: principles and strategies. Ann Thorac Surg 1999; 68:1983.
  3. Russo MJ, Iribarne A, Hong KN, et al. Factors associated with primary graft failure after heart transplantation. Transplantation 2010; 90:444.
  4. Russo MJ, Chen JM, Sorabella RA, et al. The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2007; 133:554.
  5. Appleyard RF, Cohn LH. Myocardial stunning and reperfusion injury in cardiac surgery. J Card Surg 1993; 8:316.
  6. García-Poblete E, Fernández H, Alvarez L, et al. Structural and ultrastructural study of the myocardium after 24-hour preservation in University of Wisconsin solution. Histol Histopathol 1997; 12:375.
  7. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 2000; 19:909.
  8. Potapov EV, Loebe M, Hübler M, et al. Medium-term results of heart transplantation using donors over 63 years of age. Transplantation 1999; 68:1834.
  9. Marelli D, Laks H, Fazio D, et al. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 2000; 19:496.
  10. Jeevanandam V, Furukawa S, Prendergast TW, et al. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 1996; 62:1268.
  11. McNamara D, Di Salvo T, Mathier M, et al. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression. J Heart Lung Transplant 1996; 15:506.
  12. Emery RW, Miller LW. Handbook of Cardiac Transplantation, Lippincott Williams & Wilkins, Philadelphia 1996. p.129.
  13. Dawson KL, Parulekar A, Seethamraju H. Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 2012; 31:1325.
  14. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant 2011; 30:1078.
  15. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22:58.
  16. Skowronski EW, Epstein M, Ota D, et al. Right and left ventricular function after cardiac transplantation. Changes during and after rejection. Circulation 1991; 84:2409.
  17. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med 1991; 324:1791.
  18. Halle AA 3rd, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995; 26:120.
  19. Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992; 11:892.
  20. Bhalodolia R, Cortese C, Graham M, Hauptman PJ. Fulminant acute cellular rejection with negative findings on endomyocardial biopsy. J Heart Lung Transplant 2006; 25:989.
  21. Costanzo-Nordin MR, Heroux AL, Radvany R, et al. Role of humoral immunity in acute cardiac allograft dysfunction. J Heart Lung Transplant 1993; 12:S143.